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ABSTRACT
Background
In breast cancers, only a minority of patients fully benefit from the different chemotherapy
regimenscurrentlyinuse.Identificationofmarkersthatcouldpredicttheresponsetoaparticular
regimen would thus be critically important for patient care. In cell lines or animal models, tumor
protein p53 (TP53) plays a critical role in modulating the response to genotoxic drugs. TP53 is
activated in response to DNA damage and triggers either apoptosis or cell-cycle arrest, which
have opposite effects on cell fate. Yet, studies linking TP53 status and chemotherapy response
have so far failed to unambiguously establish this paradigm in patients. Breast cancers with a
TP53 mutation were repeatedly shown to have a poor outcome, but whether this reflects poor
response to treatment or greater intrinsic aggressiveness of the tumor is unknown.
Methods and Findings
In this study we analyzed 80 noninflammatory breast cancers treated by frontline
(neoadjuvant) chemotherapy. Tumor diagnoses were performed on pretreatment biopsies,
and the patients then received six cycles of a dose-dense regimen of 75 mg/m
2 epirubicin and
1,200 mg/m
2 cyclophosphamide, given every 14 days. After completion of chemotherapy, all
patients underwent mastectomies, thus allowing for a reliable assessment of chemotherapy
response. The pretreatment biopsy samples were used to determine the TP53 status through a
highly efficient yeast functional assay and to perform RNA profiling. All 15 complete responses
occurred among the 28 TP53-mutant tumors. Furthermore, among the TP53-mutant tumors,
nine out of ten of the highly aggressive basal subtypes (defined by basal cytokeratin [KRT]
immunohistochemical staining) experienced complete pathological responses, and only TP53
status and basal subtype were independent predictors of a complete response. Expression
analysis identified many mutant TP53-associated genes, including CDC20, TTK, CDKN2A, and the
stem cell gene PROM1, but failed to identify a transcriptional profile associated with complete
responses among TP53 mutant tumors. In patients with unresponsive tumors, mutant TP53
status predicted significantly shorter overall survival. The 15 patients with responsive TP53-
mutant tumors, however, had a favorable outcome, suggesting that this chemotherapy
regimen can overcome the poor prognosis generally associated with mutant TP53 status.
Conclusions
This study demonstrates that, in noninflammatory breast cancers, TP53 status is a key
predictive factor for response to this dose-dense epirubicin–cyclophosphamide regimen and
further suggests that the basal subtype is exquisitely sensitive to this association. Given the
well-established predictive value of complete responses for long-term survival and the poor
prognosis of basal and TP53-mutant tumors treated with other regimens, this chemotherapy
could be particularly suited for breast cancer patients with a mutant TP53, particularly those
with basal features.
The Editors’ Summary of this article follows the references.
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Breast cancers are a heterogeneous group of tumors. While
most breast cancer patients receive chemotherapy, less than
20% of those receiving neoadjuvant treatment will reach
complete pathological response (disappearance of invasive
tumor cells in pathological tissue samples), which strongly
predicts long-term survival [1–5]. Predictive molecular
determinants for conventionally dosed chemotherapy re-
sponses are only emerging [6–8], and very little is known
regarding prediction of response to dose-dense treatments.
Tumor protein p53 (TP53), the prototypic tumor suppressor
gene, is a master gene of stress response that plays a key role
in cancer development. TP53 is a transcription factor that
controls the expression of many genes implicated in
apoptosis (PUMA and BAX) or cell-cycle regulation (SFN
and CDKN1A). In animal or cell-line models, TP53 was shown
to play a critical role in the response to DNA damage induced
by a number of anticancer therapies [9]. In fact, TP53
inactivation may promote an exquisite sensitivity to some
agents, but resistance to others [10].
The role of TP53 status in determining the response to a
given cytotoxic treatment in patients is largely unsettled, in
part because of technical difﬁculties in establishing TP53
status in the clinical setting, and because most studies
analyzed survival rather than initial tumor response. While
tumor disappearance is a direct and unambiguous measure of
chemotherapy efﬁciency, survival is a composite endpoint,
which incorporates not only the efﬁciencies of the different
treatments, but also the intrinsic aggressiveness of the disease.
In hematological malignancies, several studies have found
that mutant TP53 status is associated with treatment failure
[11,12]. Similarly, in breast cancer, patients with TP53-mutant
tumors often have poor responses to therapy and/or shorter
survival than those with normal TP53 [13–17].
Here, we have used a highly sensitive functional TP53 assay,
which not only determines the functional impact of TP53
mutations, but also explores other dysfunctions, such as
splicing defects [18], to analyze a group of breast cancer
patients treated with a neoadjuvant dose-intense chemo-
therapy regimen.
Methods
Patients
Two hundred and six patients with inﬂammatory and
noninﬂammatory breast cancers treated at a single institution
from1997to2003underwentopenincisionalbiopsy(0.5–3cm
in size) followed by ﬁrst-line chemotherapy and consented to
the study (Tables 1 and S1). One hundred and twenty six
patients were not included for the following reasons:
inﬂammatory breast cancer (78 tumors), frozen tumor tissue
absent or unsuitable for RNA analysis (29 tumors), absence of
further mastectomy (16 cases) or undeﬁned response (three
cases: patients P80, P81, P83; see below). The 80 remaining
patients were treated with exactly the same regimen (75 mg/m
2
epirubicin and 1,200 mg/m
2 cyclophosphamide, delivered
every 14 d [19] with granulocyte-colony stimulating factor
support in case of febrile neutropenia) and had unambiguous
pathological response data. Of the 80 patients, 35 were
included in the microarray proﬁling analysis, as were two
additional TP53-mutant tumor samples previously excluded
from the treatment response analysis as the patients had
received another treatment (patient P81) (see Table S1) or had
an initial biopsy that may have removed most of the tumor
(patient P80). A third additional patient with TP53 mutant
tumor (patient P83) (Table S1) was included for validation
studies. Patients were staged IIb, IIIa, IIIb, or IV [20], except
four patients (Tables 1 and S1) with a T2N0M0 (stage IIa)
disease who had documented tumor doubling time of less than
6 mo (two cases) or who had tumors over 3 cm in size (two
cases). The group of 80 patients included in the study was not
differentfromthe48excludedpatients withnoninﬂammatory
breast cancer patients in terms of age and TNM Classiﬁcation
of Malignant Tumors stage [20] with, respectively, median age
48 y (24–76 y) and 52 y (29–74 y) and TNM: T1, 0% and 5%; T2,
14% and 19%; T3, 45% and 43%; T4, 41% and 33%; Nþ, 75%
and 71%; and Mþ, 19% and 13%. Tumors were graded
according to the modiﬁed Scarff, Bloom, and Richardson
system [21]. All patients were screened for metastasis at
diagnosiswithatleastchest x-ray,liverultrasound, orthoraco-
abdomino-pelvic CT scan and bone scintigram. At the time of
diagnosis 11 patients had metastases (Table S1). After
completion of the planned six cycles of primary chemo-
therapy—thus approximately 3 mo after diagnosis—the
patients underwent mastectomy and axillary lymph node
dissection. Pathologically assessed complete response was
deﬁned by the complete disappearance of invasive tumor
cells in the mastectomy specimen and in the lymph nodes or a
single microscopic invasive focus (P4) or residual breast in situ
carcinoma (P42, P46, and P69), as previously described [22].
TP53 Typing
TP53 status was determined by the yeast functional assay, in
which mutant TP53 transcripts yield red yeast colonies and
wild-type transcripts yield white ones [23]. Tumors were
considered TP53 mutant when: (i) more than 15% of the yeast
colonies were red, (ii) analysis using the split versions of the
test could identify the defect in the 59 or 39 part of the gene,
conﬁrming the initial determination [24], and (iii) sequence
Table 1. Description of the 80 Patients Analyzed for Chemo-
therapy Response
Patient or Tumor Features Specific Classes n Percentage
Age  50 y 50 62
.50 y 30 38
Disease stage Stage IIA 4 5
Stage IIB 9 11
Stage IIIA 30 37
Stage IIIB 26 33
Stage IV 11 14
Histological type Ductal type 69 88
Lobular type 10 13
Mucinous type 1 1
Tumor grade Grade 1 1 1
Grade 2 37 46
Grade 3 42 53
ESR1 status by IHC ESR1
neg 23 29
ESR1
pos 57 71
ERBB2 status by RT-PCR ERBB2
neg 62 77
ERRB2
pos 18 23
doi:10.1371/journal.pmed.0040090.t001
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unambiguous genetic defect (mutation, deletion, or splicing
defects) (Table S2). All tumors with more than 15% red
colonies fulﬁlled these three criteria. Note that the four
tumors with low percentage of mutant colonies (15%–25%)
all exhibited stop or frame-shift mutations, defects known to
be associated with nonsense mediated RNA decay, resulting
in low mRNA abundance (Table S2). Prediction of dominant
negative activity was performed using IARC software (http://
www-p53.iarc.fr/index.html).
RNA Analysis
RNA was prepared as previously [22], yielding 2–83 lg
(mean 17 lg) of RNA. Its quality was veriﬁed by Agilent
bioanalyzer (http://www.home.agilent.com), and Affymetrix
arrays (http://www.affymetrix.com) were performed after a
single or a double round of ampliﬁcation (Table S1). RT-PCR
was performed using Gene Expression Assays (Applied
Biosystems, http://www.appliedbiosystems.com), except for
the CDKN2A locus for which we designed speciﬁc primers
(available upon request).
Immunohistochemistry
Immunohistochemical analyses were carried out on paraf-
ﬁn sections using antibodies directed against estrogen
receptor 1 (ESR1) (clone 6F11) (Novocastra, http://www.vi-
sion-bio.com), keratin 5/6 (KRT5/6) (clone D5/16 B4) (Dako-
Cytomation, http://www.dako.com), keratin 17 (KRT17) (clone
E3) (DakoCytomation), cyclin-dependent kinase inhibitor 2A
(CDKN2A [p16] (clone E6H4) (DakoCytomation), and on
frozen sections using antibodies directed against prominin 1
(PROM1 [CD133/1]) (clone AC133) (Miltenyi Biotec, http://
www.miltenyibiotec.com). Basal KRT (5/6 or 17) or PROM1
were scored positive if strong cytoplasmic staining was
observed in any invasive carcinoma cells [25,26]. For all other
antibodies, there was either no staining (negative cases) or a
positive staining in more than 10% of tumor cells (positive
cases) either in nucleus (ESR1, CDKN2A) and/or in cytoplasm
(CDKN2A).
Statistics and Bioinformatics
Microarray data analysis was based on 37 tumor samples
(Table S1): 29 (set S1) processed using the one-cycle target
labeling protocol (Affymetrix), and eight (set S2) processed
using the two-cycle target-labeling protocol. RT-PCR data
analysis was based on 82 tumor samples: 37 from the
microarray series (S1 þ S2) and 45 new samples (set S3).
Except as indicated, all transcriptome analysis was carried out
using either an assortment of R-system software (version
1.9.0) packages including those of Bioconductor (version
1.1.1) (http://www.bioconductor.org) or original R code. Raw
feature data from Affymetrix HG-U133A GeneChip micro-
arrays were normalized using RMA method (R package affy
version 1.4.32), which yielded log2 intensity expression
summary values for each of the 22,283 probe sets. Each set
(S1 and S2) was normalized independently. Individual feature
data from set S1 and S2 were normalized in batches along
with an additional 17 (one-cycle) and 19 (two-cycle) samples
unrelated to this study, respectively. Probe sets correspond-
ing to control genes or having an ‘‘x’’ annotation were
masked, leaving 19,987 probe sets for further analyses.
Clustering analysis of the samples was performed using
DNA-Chip Analyzer software (dChip version 1.3, http://www.
dchip.org) with (1   Pearson correlation coefﬁcient) as
distance metric and Centroid linkage. The RMA normalized
data of 37 samples (S1 þ S2) were used in this analysis, based
on a subset of 990 probe sets. These 990 probe sets were
selected using only set S1 based on the two following criteria:
(i) a robust coefﬁcient of variation (rCV) superior to the 95th
rCV percentile and below 10, and (ii) a p-value of a variance
test (see below) less than 0.01. For each probe set, rCV was
calculated by ﬁrst eliminating the highest and lowest
expression values for that probe set out of all of the samples.
From the remaining samples we divided the standard
deviation of the expression values by the mean expression
values. This yielded an rCV value for each probe set. The
variance calculated for each probe set P (variance across all
samples) was compared to the median variance from all
19,987 probe sets. The statistic used was ([n   1] 3 Var(P)/
Varmed), where n refers to the number of samples. This
statistic was compared to a percentile of the Chi
2 distribution
with (n   1) degrees of freedom (this criterion is used in the
BRB Array Tools ﬁltering tool, described in the user’s manual
[http://linus.nci.nih.gov/BRB-ArrayTools.html]) and yielded a
p-value for each probe set.
We performed all univariate t- and F-tests using BRB Array
Tools (version 3.0 b2) on the RMA normalized data for the
19,787 probe sets. We designated a signiﬁcance level of each
univariate test of p , 0.001 (except when otherwise
indicated). To evaluate the number of false positives (due to
multiple testing), we used a Monte Carlo approach (imple-
mented in BRB comparison tool) based on 1,000 random
sample label permutations. This method calculates the false
discovery rate (with a probability of 90%), on the basis of the
number (n) of probe sets (n ﬁrst probe sets ordered by their p-
value from the univariate test) identiﬁed where the false
discovery is relative to the chosen level of signiﬁcance for the
univariate test (e.g., p¼0.001). This method also evaluates the
number n9 of probe sets (n9 ﬁrst probe sets ordered by their p-
value from the univariate test) for which the number of false
discoveries is less than 10 (with a probability of 90%). See
Dataset S1 for the statistics related to the deﬁnitions of the
genes associated with the C1, C2, and C3 groups.
Based on the t-tests of TP53 status described above, we
sorted the 1,599 obtained probe sets by fold change (ratio of
the geometric mean intensity in the 17 TP53 mutant samples
versus the geometric mean intensity in the 12 TP53 wild-type
samples). We then selected the ten well-characterized probe
sets having the highest fold change: 204304_s_at (PROM1),
205347_s_at (TMSNB), 209016_s_at (KRT7), 213338_at
(RIS1), 209803_s_at (PHLDA2), 36711_at (MAFF),
202912_at (ADM), 204822_at (TTK), 202870_s_at
(CDC20), and 207039_at (CDKN2A) (219010_at [FLJ10901]
was ﬁltered, as it is not well characterized). We also selected
ESR1 (second highest inverse fold change). This yielded 12
gene transcripts for further study with RT-PCR (for CDKN2A
we used two targets: p14 and p16). Due to a lack of sample
RNA, only 948 data points (Ct [gene, sample]) from a total of
984 possible data points (12 genes 3 82 samples) were
available. These Ct values were normalized to yield ddCt
values, based on the following calculation: for a given sample
s, ddCtgene(s) ¼ dCtgene(s)   (Median of dCtgene across all
samples), with dCtgene(s) ¼ Ctgene(s)   Ctcalibrator(s), using the
gene TBP (TATA-binding protein) as the reference gene. See
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Chemosensitive p53-Mutant Breast CancersDataset S1 for the statistics associated with the RT-PCR data
of these 12 genes.
Statistical Methods for the Analysis of the Clinical Data
The association between treatment response and potential
prognostic variables (age, tumor grade, cytoplasmic staining
of CDKN2A, presence of KRT5/6 or 17, ERBB2 mRNA
expression, ESR1 protein expression, T stage from TNM
classiﬁcation, and TP53 mutation status) was tested using
Fisher’s exact test. Because the age of the patients represents
a continuous variable, patients were divided into two classes
using a cutoff at age 50. Stratiﬁed association analyses were
performed using the Mantel-Haenszel test. Kaplan-Meier
survival curves and log-rank p-values were calculated on the
basis of either event-free survival (considering local relapse or
distant metastasis as an event) in the population of patients
that were free of metastasis at diagnosis or overall survival on
the complete population.
Results
All Complete Responses to a Dose-Dense Chemotherapy
Harbor TP53 Mutations
We had previously observed, in 49 of our 206 patients, that
complete responses were preferentially achieved when
tumors bore TP53 mutations [22]. Analysis of the consecutive
cohort of 31 patients independently validated this association
(p ¼ 0.0003), which became compelling (p ¼ 10
 8) when the
initial subset and the consecutive cohort were pooled (Figure
1A). Indeed, not a single tumor with a normal TP53 genotype
(52 cases) had a complete response, while 15 out of 28 TP53-
mutant tumors exhibited complete pathological responses.
The predicted effects of the observed mutations and the
distribution of R72P polymorphism were not signiﬁcantly
different in tumors with complete or incomplete responses
(Table S2).
TP53 Status and Basal Features Are Independent
Predictors of Complete Response
Many studies have demonstrated that mutant TP53 status is
tightly associated with ESR1
neg and grade 3 breast cancers. In
addition, ESR1
pos status was previously associated with
chemotherapy resistance [7]. To elucidate the respective
contribution of these factors in predicting chemotherapy
response, we analyzed the distribution of age, T stage (from
TNM classiﬁcation), tumor grade, TP53 status, staining for
ESR1, KRT5/6 or 17, and ERBB2 RNA expression among the
80 patients (Figure 1A; Tables 1 and S1). We also included
staining for CDKN2A, a major tumor suppressor whose
Figure 1. Response to Chemotherapy
(A) Top: distribution of the pathological response to chemotherapy of the 80 patients according to TP53 status as well as other clinical or biological
annotations. T, T stage from the TNM classification. p-Values are below each contingency table. Bottom: results from adjusted Chi
2 tests. The variables
tested for the prediction of complete response are shown in the columns; the stratification variable is listed in the first column. The p-values are color
coded (dark yellow and bold type, p , 0.0001; light yellow, 0.0001 , p , 0.01).
(B) Left graph: Kaplan-Meier analysis of the event-free survival of the patients without metastatic extension at diagnosis, all treated with the same
regimen (including patient P80, see Table S1). Note that all five relapses in the TP53 mutant group occurred in the first 18 months, while in the TP53
wild-type group, relapses were still observed when survival of many patients was censored. Right graph: overall survival stratified by TP53 status and
complete response.
doi:10.1371/journal.pmed.0040090.g001
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High transcript and protein levels of CDKN2A are associated
with cytoplasmic staining (Figure S1). Therefore we used the
cytoplasmic staining pattern as the criteria for deeming a
sample CDKN2A positive or negative, as in previous studies
[27–29]. No or weakly signiﬁcant differences in age, T stage,
or ERBB2 status were found between complete and incom-
plete responses. In contrast, grade, TP53 status, ESR1, KRT5/6
or 17, and cytoplasmic CDKN2A (p16) staining were all
strongly associated with response (Figure 1A). As there are no
complete responses in the TP53 wt group, the estimation of a
regression coefﬁcient using the multivariate logistic regres-
sion model is impossible, this coefﬁcient being theoretically
inﬁnite in such a situation, precluding a multivariate analysis.
Yet, TP53 status remained signiﬁcantly linked to a response
in univariate analyses, irrespective of the stratiﬁcation (age, T
stage or tumor grade, KRT5/6 or 17 presence, CDKN2A
cytoplasmic staining [p16], ERBB2 mRNA, or ESR1 protein
expression) in Mantel-Haenszel tests (Figure 1A). In contrast,
with the exception of basal features (KRT5/6 or 17 positivity),
all the other individually signiﬁcant variables signiﬁcantly
associated with complete response prior to stratiﬁcation for
TP53 (Figure 1A) no longer remained signiﬁcant after
stratiﬁcation for TP53 status (Figure 1A). Moreover, among
the patients with TP53 mutations, the 15 tumors with a
complete response had sizes and grades (six T2s, ﬁve T3s, and
four T4s, all grade 3) comparable to the 13 who did not reach
a complete response (three T2s, ﬁve T3s, and ﬁve T4s, all but
one grade 3). Altogether, despite the impossibility of a formal
multivariate regression analysis, it appears that TP53 and, to a
lesser extent, basal features are the only important predictors
of complete pathological response.
TP53 Status and Survival
When patients with metastatic disease at diagnosis were
excluded from the analysis, most patients with a TP53 mutant
tumor had favorable event-free survival, although with the
current median follow-up (46 mo, range 3–103 mo), it did not
reach statistical signiﬁcance (Figure 1B, left graph; Table S1).
Patients with a basal phenotype or complete responses also
had favorable outcomes (Table S1), in line with the well-
known association between a complete response and pro-
longed survival [1–5]. This observation is particularly re-
markable, because TP53 mutant tumors have been reported
in several studies to have a shorter survival than TP53 wild-
type ones [13,14,30,31]. Patients with wild-type TP53 tumors
had a relatively favorable overall survival, despite the lack of
complete response (Figure 1B, right graph, red curve).
Interestingly, patients with TP53-mutant tumors who did
not reach complete response had a signiﬁcantly shorter
overall survival than other tumors (p ¼0.02) (Figure 1B, right
graph, orange curve). Again, absence of complete responses
in the wild-type TP53 group precluded a multivariate survival
analysis.
Can Transcriptional Profiling Predict Complete Response?
In an attempt to better characterize the responsive tumors,
we performed expression analyses using microarrays. Of the
83 (three additional TP53 mutant tumor samples were
considered for the proﬁling study, see Methods) breast
tumors considered for gene-proﬁling analysis, 37 had enough
high-quality RNA extracted from biopsies before chemo-
therapy to be analyzed with the arrays, leaving the remaining
46 samples for validation studies. Consistent with previous
reports [32], hierarchical cluster analyses of these 37 cancers
identiﬁed three robust clusters of patients (C1, C2, and C3), as
well as the genes deﬁning these patients’ clusters (Figure 2A;
Tables S3–S5).
To deﬁne genes speciﬁcally associated with complete
responses, we then performed t-tests based on the Affymetrix
data on the 28 tumors (nine complete responses and 19
incomplete responses) processed using a single ampliﬁcation
step (see Methods). We identiﬁed 77 probe sets using a p-value
threshold of 0.001, with a high false discovery rate of 26%
(Table S6). Using the same sample population, we identiﬁed
1,599 TP53 mutant–associated genes, with a false discovery
rate less than 0.1%. As expected, the great majority (54 of 77)
of genes associated with complete response were also TP53-
associated genes, the others most likely being false positive
(Table S7). Importantly, within the subgroup of TP53 mutant
tumors, t-tests failed to identify more genes associated with
complete responses than would be expected by chance.
Examining the genes associated with TP53 status, we found
that, as expected, wild-type TP53 tumors overexpressed many
ESR1-associated genes [30,32,33], as well as ribosomal protein
genes (Figure 2B). In contrast, TP53 mutant tumors overex-
pressed, among others, a number of master genes (such as
PROM1, cell division cycle 20 homolog [CDC20], CDKN2A, TTK
protein kinase [TTK], and adrenomedullin [ADM]) (Figure 2B;
Table S7). Most of these mutant TP53 associated genes did not
overlap with the ones described in a recent study that used
direct TP53 sequencing and a different chip [14]. To exclude
the possibility that the genes associated with TP53 mutant
status might merely reﬂect ESR1
neg status, we repeated this
analysis within the subgroup of ESR1
pos tumors. We again
found six out of the top ten genes previously identiﬁed
among 15 top genes differentiating TP53-mutant versus wild-
type tumors (Table S8) within the ESR1
pos subgroup,
demonstrating that the TP53-mutant genes that we have
identiﬁed do not simply reﬂect ESR1
neg status. In order to
validate these mutant TP53-associated genes, we then assessed
by quantitative RT-PCR the levels of expression of the ﬁrst
ten genes with the largest fold difference (Figure 2B; Table
S7), as well as ESR1. Most of the 12 gene transcripts tested
showed signiﬁcant differences between TP53-mutant or wild-
type tumors, not only in the tumor set used to select those
genes, but also in the rest of the samples, the ESR1
pos
subgroup, and the complete population (Dataset S1; Figure 3).
To characterize the highly chemosensitive tumors that
express the KRT5/6 or KRT17 proteins by immunohisto-
chemistry, we performed t-tests based on the Affymetrix data
of TP53 mutant tumors and found overexpression of basal
cytokeratins and many genes previously identiﬁed in myoe-
pithelial cells, consistent with the proposed origin of these
tumors (Table S9) [26].
Lastly, we compared transcript levels to the immunohis-
tochemical detection of ESR1, CDKN2A (p16), PROM1,
KRT5, and KRT17 in all samples, which demonstrated very
signiﬁcant differences in mRNA levels between immunohis-
tochemistry (IHC)þand IHC tumors (p , 0.001) (Figure S1).
In particular, in most of the TP53-mutant and nine out of ten
of the basal tumors (deﬁned as KRT5- or KRT17-staining),
PROM1 staining was strongly positive in a few cancer cells
that could be breast cancer stem cells.
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We show that in noninﬂammatory breast cancers, TP53
mutations are highly predictive of complete responses to a
dose-intense neoadjuvant epirubicin–cyclophosphamide che-
motherapy regimen. Why did previous studies fail to identify
this relationship? We believe that the results reported here
reﬂect the use of a very aggressive DNA-damaging regimen
and of a highly efﬁcient technique to determine TP53 status,
which detects not only mutations and deletions, but also
abnormal splicing events [18]. It is also possible that some
previous studies were biased by the presence of inﬂammatory
breast cancers in the study population.
As TP53 is a master gene controlling acute DNA-damage
response, its functional integrity was expected to control cell
survival, particularly after a dose-dense regimen triggering
both double-strand breaks and DNA cross-links. TP53
activation induces a plethora of biological responses (tran-
sient cell cycle arrest, senescence, and/or apoptosis) that may
have opposing effects on cancer therapy responses [34]. TP53
or CDKN1A deﬁciencies, which impede chemotherapy-
induced cell-cycle arrest, dramatically increase anthracyclin-
induced cell death ex vivo [10]. TP53-induced cell-cycle arrest
should also protect cells from cyclophosphamide, which, in
vivo, only kills rapidly cycling cells [35]. Note that one of the
few genes induced by chemotherapy in breast cancers is p21
CDKN1A [36]. In contrast, TP53-mutant cells that cannot
arrest in the cell cycle would subsequently progress towards
mitotic catastrophe [10,37]. Topoisomerase II A (TOP2A)
expression is an important determinant of epirubicin
response [38]. When we investigated the expression of TOP2A
by RT-PCR in all the samples, no signiﬁcant differences in
transcript levels were observed between responsive and
unresponsive tumors, independently of their TP53 status
(unpublished data). We suggest that the very high dose of
cyclophosphamide used here bypasses the inﬂuence of Top2A
in controlling response to epirubicin. Whatever the exact
mechanism(s) involved, the exquisite chemosensitivity of
Figure 2. Microarray Data
(A) Hierarchical clustering based on the 990 most varying genes in 37 tumors with Affymetrix-grade RNA. C1, C2, and C3 denote the three tumor
clusters. Annotations: TP53 status (red, mutant; yellow, wild-type); ESR1 (immunohistochemistry) (blue, positive; green, negative); basal cytokeratins
(KRT5/6 or 17, immunohistochemistry) (orange, positive; gray, negative); ERBB2 (RT-PCR) (pink, positive; gray, negative); complete pathological response
to chemotherapy (blue, complete; red, incomplete); and tumor grade (green, grade 3; purple, grade 1 or 2). For chemotherapy response, patients
treated with other regimens are indicated by a question mark. P1, P2, etc. refer to the patient’s references in Table S1.
(B) Genes linked to TP53 status (t-tests): the top and bottom genes (classified by fold changes [FC]) are shown.
doi:10.1371/journal.pmed.0040090.g002
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Chemosensitive p53-Mutant Breast CancersTP53 mutant breast cancers strongly favors the hypothesis
that here, TP53 activation principally blocks cell cycle
progression, rather than triggering a cell death program
[34]. In line with our observations, transient pharmacological
inhibition of TP53 was recently proposed to boost chemo-
therapy efﬁcacy [39].
The expression studies performed here have identiﬁed and
validated a transcriptional proﬁle associated with mutant
TP53 status (and hence indirectly to response), but failed to
identify, within the TP53 mutant group, a speciﬁc proﬁle
associated with complete response. Yet, many of these TP53
mutant–associated genes would be helpful tools in character-
izing the pathophysiology of these tumors. PROM1, a marker
of normal or cancer stem cells [40], is the gene with the
highest fold-difference in TP53-mutant breast tumors (Figure
2B) or several other tumor types (unpublished data). Basal
cancers, which were proposed to have a stem cell origin, are
virtually all TP53 mutant and express high levels of PROM1
transcript and protein (Figures 3 and S1). Very high
expression of CDKN2A transcript was associated with
cytoplasmic p16 staining (Figure S1) and was almost
exclusively observed in TP53 mutant tumors, consistent with
the absence of selection pressure for silencing of the CDKN2A
locus when TP53 is mutated. Note that several studies have
shown that cytoplasmic p16 was associated with poor survival
[27–29], while here it predicts responsiveness (Figure 1A).
Finally, a large number of cell-cycle checkpoint genes
(CDKN2A, CKS2, TTK, CDC20, CENPA, CCNB1, CCNB2, and
BUB1) were overexpressed in TP53-mutant tumors, which
may facilitate the execution of mitotic catastrophe upon
chemotherapy exposure [41].
Several studies have repeatedly demonstrated worse out-
comes for patients with TP53-mutant breast tumors when
treated with a standard regimen, implying that mutant TP53
is a poor prognostic factor [13,14,16,30]. In our study, mutant
TP53 was the major independent predictive factor of
complete pathological responses, which itself is the major
predictor of long-term survival in patients previously treated
with the same protocol [3]. Accordingly, TP53-mutant
patients from this study appeared to have a more favorable
event-free survival than those with a wild-type TP53 (Figure
1B). However, if patients with TP53-mutant tumors failed to
reach a complete response, their survival was signiﬁcantly
worse than those with TP53 wild-type, unresponsive tumors (p
¼ 0.02, Figure 1B), consistent with previous studies. The
coexistence, among TP53-mutant tumors, of two very differ-
ent types of tumors (i.e., the responsive ones with good
prognosis and the unresponsive ones with very poor
prognosis) may account for the conﬂicting results of the
literature regarding the prognostic value of TP53 status in
breast cancer. The apparent paradox between the results of
our study and previous ones is likely treatment-related, as the
Figure 3. Validation of Mutant TP53 Profile in Breast Cancers
For each of the 12 most varying genes (11 overexpressed and one underexpressed), four box plots are shown, representing the distribution of the ddCt
values for the four following groups of samples: (i) TP53 mutant from the training set (empty red box), (ii) TP53 wild type from the training set (empty
blue box), (iii) TP53 mutant from the validation set (filled red box), and (iv) TP53 wild type from the validation set (filled blue box). *p , 0.05; **p , 0.01,
***p , 0.001 (t-tests). Small circles indicate outliers.
doi:10.1371/journal.pmed.0040090.g003
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Chemosensitive p53-Mutant Breast Cancersregimen used here had a dose intensity two to four times
higher than most others, with only two-week intervals
between courses. However, some recent studies are in line
with our data: ESR1
neg breast cancers (which are mostly TP53
mutant) were found to be more sensitive to neoadjuvant
chemotherapy [7] and, in a pilot study, TP53 staining was
associated with favorable responses to preoperative anthra-
cyclins [42]. Despite the small number of cases analyzed, our
data also suggest that basal cancers, described as having a
dismal prognosis in all other studies [25,26,33,43], are
exquisitely sensitive to this association, possibly because of
their rapid proliferation, which favors cyclophosphamide-
induced cell death [35,43]. Thus, TP53-mutant tumors may
have a poor outcome when treated with conventionally dosed
chemotherapies, but may be highly responsive to dose
intensiﬁcation. Hence, in the neoadjuvant, or even in the
adjuvant settings [44], this type of dose-intense regimen could
be particularly suited for patients with basal and TP53-
mutant tumors.
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Table S1. Characteristics of Patients and Tumors
Sets: S1, single ampliﬁcation for microarray; S2, double ampliﬁcation
for microarray; S3, tumors not analyzed by microarray, but used for
RT-PCR and/or immunohistochemical studies. The raw data for
quantitative RT-PCR analysis (ddCT) or other immunohistochemical
tests are highlighted in yellow. C, complete; DOD, died of disease; EC,
epirubicin/cyclophosphamide; ET, epirubicin/docetaxel; KRT, cyto-
keratin; NA, not applicable; NC, not complete; nd, not done; wd,
without disease; META, metastatic; METADiag, metastatic at diag-
nosis; TNM, tumor, node, metastasis.
Found at doi:10.1371/journal.pmed.0040090.st001 (52 KB PDF).
Table S2. Summary of the Data on the 28 TP53 Mutations in Patients
Studied for Pathological Response to Chemotherapy
FASAY, functional analysis of separated allele in yeast [23,24] codon
72; R, arginine; P, proline.
Found at doi:10.1371/journal.pmed.0040090.st002 (28 KB PDF).
Table S3. Genes Speciﬁc for Patient Cluster 1
Probe set, ratios of mean values, p-values, gene symbol, and gene
name are indicated. Class speciﬁc gene lists were generated by the
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(i.e., C1-speciﬁc genes, intersection of C1 versus C2, C1 versus C3 and
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genes were identiﬁed.
Found at doi:10.1371/journal.pmed.0040090.st007 (46 KB PDF).
Table S8. List of Probe Sets Associated with TP53 Mutant Status in
the Subgroup of ESR1
pos Tumors
Note that several of the top genes (when ordered by decreasing fold-
change values) were previously identiﬁed in the complete population
(Table S7). Genes in common with Table S7 are highlighted.
Found at doi:10.1371/journal.pmed.0040090.st008 (31 KB PDF).
Table S9. Genes Identiﬁed by t-Tests of TP53-Mutant KRT5/6
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KRT17
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Accession Numbers
The primary data for the microarrays were deposited at the
European Bioinformatics Institute (EBI) Web site (http://www.ebi.ac.
uk) (ArrayExpress number E-TABM-43). Accession numbers for the
genes and corresponding proteins cited in the main text are given
below in PubMed format (gene, NM_; protein, NP_): PROM1
(NM_006017, NP_006008); TMSNB (NM_021992, NP068832);
KRT7 (NM_005556, NP_005547); RIS1 (NM_057212,
NP_476560); PHLDA2 (NM_003311, NP_003302); MAFF
(NM_010755, NP_034885); ADM (NM_001124, NP_001115); TTK
(NM_003318, NP_003309); CDC20 (NM_001255, NP_001246);
CDKN2A (NM_000077, NP_000068); CDKN2A (NM_058195,
NP_478102); ESR1 (NM_000125, NP_000116); ERBB2
(NM_001005862, NP_001005862); KRT5 (NM_000424,
NP_000415); KRT6 (NM_080747, NP_542785); KRT17
(NM_000422, NP_000413); TOP2A (NM_001067, NP_001058.2);
PUMA (NM_014417 , NP_055232); BAX (NM_138763,
NP_620118); TP53 (NM_000546,NP_006133); BUB1 (NM_004336,
NP_000380); CCNB2 (NM_004701, NP_004692); CDKN1A
(NM_000389, NP_000380); CCNB1 (NM_031966, NP_114172);
CENPA (NM_001809, NP_001800); and CKS2 (NM_001827,
NP_001818.1).
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Chemosensitive p53-Mutant Breast CancersEditors’ Summary
Background. One woman in eight will develop breast cancer during her
life. As with other cancers, breast cancer arises when cells accumulate
genetic changes (mutations) that allow them to grow uncontrollably and
to move around the body. These altered cells are called malignant cells.
The normal human breast contains several types of cell, any of which can
become malignant. In addition, there is more than one route to
malignancy—different sets of genes can be mutated. As a result, breast
cancer is a heterogeneous disease that cannot be cured with a single
type of treatment. Ideally, oncologists would like to know before they
start treating a patient which therapeutic approach is going to be
successful for that individual. Recently, researchers have begun to
identify molecular changes that might eventually allow oncologists to
make such rational treatment decisions. For example, laboratory studies
in cell lines or animals indicate that the status of a gene called TP53
determines the chemotherapy agents (drugs that preferentially kill
rapidly dividing cancer cells) to which cells respond. p53, the protein
encoded by TP53, is a tumor suppressor. That is, in normal cells it
prevents unregulated growth by controlling the expression of proteins
involved in cell division and cell death. Consequently, p53 is often
inactivated during cancer development.
Why Was This Study Done? Although laboratory studies have linked
TP53 status to chemotherapy responses, little is known about this
relationship in human breast cancers. The clinical studies that have
investigated whether TP53 status affects chemotherapy responses have
generally found that patients whose tumors contain mutant TP53 have a
poorer response to therapy and/or a shorter survival time than those
whose tumors contain normal TP53. In this study, the researchers have
asked whether TP53 status affects tumor responses to a dose-intense
chemotherapy regimen (frequent, high doses of drugs) given to women
with advanced noninflammatory breast cancer before surgery. This type
of treatment is called neoadjuvant chemotherapy and is used to shrink
tumors before surgery.
What Did the Researchers Do and Find? The researchers collected
breast tumor samples from 80 women before starting six fortnightly
cycles of chemotherapy with epirubicin and cyclophosphamide. After
this, each woman had her affected breast removed and examined to see
whether the chemotherapy had killed the tumor cells. The researchers
determined which original tumor samples contained mutated TP53 and
used a technique called microarray expression profiling to document
gene expression patterns in them. Overall, 28 tumors contained mutated
TP53. Strikingly, all 15 tumors that responded completely to neoadjuvant
chemotherapy (no tumor cells detectable in the breast tissue after
chemotherapy) contained mutated TP53. Nine of these responsive
tumors were basal-cell–like breast tumors, a particularly aggressive type
of breast cancer; only one basal-cell–like, TP53-mutated tumor did not
respond to chemotherapy. Patients whose tumors were unresponsive to
the neoadjuvant chemotherapy but contained mutated TP53 tended to
die sooner than those whose tumors contained normal TP53 or those
with chemotherapy-responsive TP53-mutated tumors. Finally, expression
profiling identified changes in the expression of many p53-regulated
genes, but did not identify an expression profile in the TP53-mutated
tumors unique to those that responded to chemotherapy.
What Do These Findings Mean? These findings indicate that non-
inflammatory breast tumors containing mutant TP53—in particular,
basal-cell–like tumors—are very sensitive to dose-dense epirubicin and
cyclophosphamide chemotherapy. Intensive regimens of this type have
rarely been used in previous studies, which might explain the apparent
contradiction between these results and the generally poor response to
chemotherapy of TP53-mutated breast tumors. More tumors now need
to be examined to confirm the association between complete response,
TP53 status and basal-cell–like tumors. In addition, although complete
tumor responses generally predict good overall survival, longer survival
studies than those reported here are needed to show that the tumor
response to this particular neoadjuvant chemotherapy regimen trans-
lates into improved overall survival. If the present results can be
confirmed and extended, dose-dense neoadjuvant chemotherapy with
epirubicin and cyclophosphamide could considerably improve the
outlook for patients with aggressive TP53-mutant, basal-cell–like breast
tumors.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040090.
  The US National Cancer Institute provides patient and physician
information on breast cancer and general information on
understanding cancer
  Cancer Research UK offers patient information on cancer and breast
cancer
  The MedlinePlus encyclopedia has pages on breast cancer
  Emory University’s CancerQuest discusses the biology of cancer,
including the role of tumor suppressor proteins
  Wikipedia has pages on p53 (note that Wikipedia is a free online
encyclopedia that anyone can edit)
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